Eli Lilly's Retatrutide shows triple-agonist clinical potential
Eli Lilly's phase 3 trial data for Retatrutide was highlighted for its potential superior efficacy in weight loss and metabolic health compared to existing GLP-1 therapies.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.